In VitroActivity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012-Reference-Cited by-同舟云学术

In VitroActivity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012

Published:2013-08-12 Issue:11 Volume:57 Page:5707-5709
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob. Agents Chemother.

Author:

Walkty A.,Karlowsky J. A.,Adam H.,Baxter M.,Lagacé-Wiens P.,Hoban D. J.,Zhanel G. G.

Abstract

ABSTRACTThein vitroactivity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435Pseudomonas aeruginosaclinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50and MIC90values for ceftolozane-tazobactam were 0.5 μg/ml and 1 μg/ml, respectively (a 32-fold-lower MIC90than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by ≤8 μg/ml of ceftolozane-tazobactam.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference20 articles.

1. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008);Canadian Antimicrobial Resistance Alliance, Hoban DJ;Antimicrob. Agents Chemother.,2010

2. Overview of nosocomial infections caused by gram-negative bacilli;National Nosocomial Infections Surveillance System;Clin. Infect. Dis.,2005

3. Occurrence and antimicrobial resistance pattern comparisons among bloodstream isolates from the SENTRY antimicrobial surveillance program (1997–2002);Biedenbach;Diagn. Microbiol. Infect. Dis.,2004

4. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY antimicrobial surveillance program (North America);Participant Group North America SENTRY;Diagn. Microbiol. Infect. Dis.,2001

5. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008–2011;Walkty;Diagn. Microbiol. Infect. Dis.,2012

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-03-12

2. Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy;Journal of Global Antimicrobial Resistance;2022-09

3. Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries;Antibiotics;2022-08-13

4. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies;Open Forum Infectious Diseases;2022-02-14

5. β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria;Beta-Lactam Resistance in Gram-Negative Bacteria;2022